摘要
目的以普罗帕酮、心律平、胺碘酮等为阳性对照,系统评价参松养心胶囊治疗室性期前收缩的治疗效果及安全性。方法按照纳入标准和排除标准收集资料和评价纳入文献质量,运用Meta分析对参松养心胶囊治疗室性期前收缩疗效及临床症状疗效进行定量综合,并评价心脏不良反应。结果纳入RCT文献26篇,共计3191例患者,其中参松组1813例,对照组1378例。室性期前收缩有效率合并效应量的检验OR(random)=1.59,95%CI为[1.27,1.99](P<0.01);临床症状有效率合并效应量的检验OR(fixed)=3.99,95%CI为[3.23,4.93](P<0.01);对照组致心律失常作用发生率为6.01%(58/961),参松组1001例致心律失常作用发生率为0%。结论参松养心胶囊治疗室性期前收缩的疾病疗效和临床症状疗效均优于抗心律失常西药,且无致心律失常作用。
Objective To systematically review the efficiency and safety of Shensongyangxin capsule compared with propafenone,propafenon and amiodarone.Methods Two observers collected data and reviewed the quality of selected literature independently,quantitatively synthesized the efficiency of premature ventricular contractions and clinical symptoms by Meta-analysis,and evaluated the heart adverse reaction.Results There were 26 articles included and 3191 patients enrolled, Shensongyangxin capsule group with 1813 cases,control group with 1378 cases.The inspection of incorporative efficiency of premature ventricular contractions effective ratio OR（random）=1.59,95%CI is[1.27,1.99]（P0.01）.The inspection of incorporative efficiency of clinical symptoms effective ratio OR（fixed）=3.99,95%CI is[3.23,4.93]（P0.01）.The arrhythmogenic effect incidence of control group was 6.01%（58/961）,and Shensongyangxin capsule treatment group（1001） is 0%.Conclusion The efficiency of Shensongyangxin capsule in treating the premature ventricular contractions and releasing clinical symptoms was better than the antiarrhythmic medicine,and no arrhythmogenic effect.
出处
《疑难病杂志》
CAS
2012年第1期6-9,共4页
Chinese Journal of Difficult and Complicated Cases
关键词
参松养心胶囊
室性期前收缩
随机对照试验
META分析
Shensongyangxin capsule
Premature ventricular contractions
Random control trial
Meta-analysis
